2026-03-172026-03-172024-10-04PARENTE, Igor Sousa e Silva. Escetamina intranasal na terapia de tratamento de transtorno depressivo maior e depressão resistente: avaliação de eficácia, segurança e impacto social. Orientadora: Ilka Lorena de Oliveira Farias; Coorientadora: Aline Andrade de Sousa. 2024. 55 f. Trabalho de Conclusão de Curso (Bacharelado em Medicina) - Faculdade de Medicina, Campus Universitário de Altamira, Universidade Federal do Pará, Altamira, 2024. Disponível em: https://bdm.ufpa.br/handle/prefix/9357. Acesso em:.https://bdm.ufpa.br/handle/prefix/9357Depressive disorders affect millions of people worldwide, being considered one of the most debilitating conditions. Although therapeutic treatment options are available, approximately half of patients fail to achieve complete remission of symptoms. Major Depressive Disorder (MDD), a severe form of depression that is often resistant to conventional treatments, is associated with a high risk of suicide. In this scenario, nasal esketamine has emerged as a promising alternative. Thus, this study had the general objective of analyzing the efficacy, safety and social impact of intranasal esketamine as a therapy in the treatment of Major Depressive Disorder and Treatment-resistant Depression, using the integrative review as methodological support. This research carried out an integrative literature review, with a time frame from 2018 to 2023, through the databases of Google Scholar, ScienceDirect, PubMed and Virtual Health Library (VHL), using the following descriptors: esketamine, intranasal administration, major depressive disorder and treatment-resistant depressive disorder. Regarding the results, it was possible to confirm that esketamine offers rapid relief from depressive symptoms, reduces the risk of relapses and accelerates recovery in times of crisis. However, some side effects, such as dissociation and increased blood pressure, were frequently reported, which highlights the importance of careful monitoring, especially among vulnerable groups, such as the elderly and patients with other health conditions. The lack of studies integrating esketamine with psychotherapeutic approaches raises the need for further research on combined treatments, which could potentially improve outcomes. In addition, non-pharmacological actions, such as music therapy, are indicated as effective in reducing adverse symptoms. One of the challenges is accessibility to treatment, in other words, the high cost and the need for constant clinical supervision limit access for many patients, reinforcing the need for public policies that promote equity in treatment. Therefore, it is concluded that, although intranasal esketamine represents an important advance in the management of these conditions, its use requires careful monitoring.Acesso AbertoEscetamina; ; ;Administração intranasalTranstorno depressivo maiorTranstorno depressivo resistente ao tratamentoEsketamineIntranasal administrationMajor depressive disorderTreatment-resistant depressive disorderCNPQ::CIENCIAS DA SAUDE::SAUDE COLETIVATrabalho de Curso - Graduação - MonografiaAttribution-NonCommercial-NoDerivs 3.0 Brazil